{
    "SPADE_UN_14457": {
        "Clinical Information": [],
        "Patent Information": [],
        "Sequence Information": {
            "SPADE ID": "SPADE_UN_14457",
            "Peptide Name": "LP-86",
            "Source": "Synthetic construct",
            "Family": "Retroviridae",
            "Gene": "Not found",
            "Sequence": "LEANIEELLKKAEEQQKKNEEELKKLEKX",
            "Sequence Length": 29,
            "UniProt Entry": [
                "http://www.uniprot.org/uniprot/P03377"
            ],
            "Protein Existence": "Not found",
            "Biological Activity": [
                "Antimicrobial",
                "Antiviral"
            ],
            "Target Organism": "[Ref.30867304]HIV-1 NL4-3(X4):inhibition of virus replication in TZM-bl cells(IC50=0.43±0.03 pM);HIV-1 JR-CSF(R5):inhibition of virus replication in TZM-bl cells(IC50=4.78±0.69 pM);HIV-1 89.6(R5X4):inhibition of virus replication in TZM-bl cells(IC50=7.24±1.36 pM);HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells(IC50=4.91 pM);T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.003±0 nM);T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.003-0.17 nM);HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=0.014-0.026 nM);SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.005-0.006 nM);HIV-1(1A,2B,1C,1G,1A/C,1A/E,1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells(IC50=12.27 pM).",
            "Hemolytic Activity": "No hemolysis information or data found in the reference(s) presented in this entry",
            "Cytotoxicity": "No cytotoxicity information or data found in the reference(s) presented in this entry",
            "Binding Target": "membrane",
            "Linear/Cyclic": "Linear",
            "N-terminal Modification": "Acetylation",
            "C-terminal Modification": "Amidation",
            "Stereochemistry": "L",
            "Structure Description": "Not found",
            "Formula": "C147H251N39O50",
            "Mass": 3494.19,
            "PI": 5,
            "Net Charge": -2,
            "Hydrophobicity": -1.576,
            "Half Life": "Mammalian:5.5 hourYeast:3 minE.coli:2 min",
            "Mechanism of action": "The peptide had extremely potent activity to block HIV envelope-mediated cell-cell fusion,showing a greatly increased potency relative to its inhibition on virus infection. Besides, it efficiently bounds to both the cellular and viral membranes to exert their antiviral activities.",
            "Literature": [
                {
                    "Title": "Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.",
                    "Pubmed ID": "30867304",
                    "Reference": "J Virol. 2019 May 15;93(11)e02312-18.",
                    "Author": "Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y.",
                    "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=30867304"
                }
            ],
            "Frequent Amino Acids": "EKL",
            "Absent Amino Acids": "CDFGHMOPRSTUVWY",
            "Basic Residues": 7,
            "Acidic Residues": 9,
            "Hydrophobic Residues": 8,
            "Polar Residues": 13,
            "Positive Residues": 7,
            "Negative Residues": 9,
            "Similar Sequences": [
                {
                    "SPADE_ID": "SPADE_UN_14344",
                    "Similarity": 1.0,
                    "Sequence": "VRYLEANIEELLKKAEEQQKKNEEELKKLE"
                },
                {
                    "SPADE_ID": "SPADE_UN_14368",
                    "Similarity": 1.0,
                    "Sequence": "VRYLEANIEELLKKAEEQQKKNEEELKKLEK"
                },
                {
                    "SPADE_ID": "SPADE_UN_14454",
                    "Similarity": 1.0,
                    "Sequence": "LEANIEELLKKAEEQQKKNEEELKKLE"
                }
            ]
        }
    }
}